Neuralstem (CUR +9.5%) trades up after saying it will provide an update on the Phase I...

|By:, SA News Editor

Neuralstem (CUR +9.5%) trades up after saying it will provide an update on the Phase I Neuralstem ALS trial of its human spinal cord stem cells, NSI-566, in the treatment of Lou Gehrig's disease. The update will be given by its principal investigator at the American Neurological Association annual meeting on Monday, October 8, 2012.